CG Oncology, Inc. (NASDAQ:CGON – Get Free Report) reached a new 52-week high during trading on Wednesday . The company traded as high as $73.91 and last traded at $73.6790, with a volume of 326846 shares. The stock had previously closed at $72.07.
More CG Oncology News
Here are the key news stories impacting CG Oncology this week:
- Positive Sentiment: Several firms reaffirmed or improved their outlook on CG Oncology, including new bullish ratings and price targets from RBC Capital ($81), JPMorgan ($96), Truist (“Buy”), and HC Wainwright (“Buy” with a $100 target), signaling continued confidence in the company’s pipeline and commercial potential.
- Positive Sentiment: Wedbush also issued a positive forecast for CGON, adding to the recent wave of supportive analyst coverage that can help drive investor sentiment and buying interest.
- Positive Sentiment: The company’s presentation at the Bank of America Global Healthcare Conference and its presence at the AUA annual meeting kept attention on CG Oncology’s non-muscle invasive bladder cancer (NMIBC) program, reinforcing visibility around its lead opportunity.
- Neutral Sentiment: HC Wainwright lowered near-term EPS estimates for 2026 and 2027 and also cut its FY2028 and FY2029 forecasts, suggesting a longer path to profitability than previously expected, though the firm still maintained a bullish rating.
- Neutral Sentiment: HC Wainwright raised its FY2030 EPS estimate, indicating stronger expected earnings power further out, but this is likely less important to the stock’s immediate trading action than the current analyst upgrades.
Wall Street Analyst Weigh In
A number of equities research analysts have commented on CGON shares. Piper Sandler raised their target price on shares of CG Oncology from $55.00 to $70.00 and gave the stock an “overweight” rating in a research note on Friday, January 16th. Royal Bank Of Canada lifted their price objective on shares of CG Oncology from $79.00 to $81.00 and gave the company an “outperform” rating in a research report on Monday. HC Wainwright lifted their price objective on shares of CG Oncology from $80.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, April 7th. Truist Financial reiterated a “buy” rating and set a $77.00 price objective (up from $75.00) on shares of CG Oncology in a research report on Monday. Finally, Wedbush lifted their price objective on shares of CG Oncology from $77.00 to $80.00 and gave the company an “outperform” rating in a research report on Monday. Eleven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $81.27.
CG Oncology Stock Up 2.7%
The business’s fifty day moving average is $66.44 and its two-hundred day moving average is $53.45. The stock has a market capitalization of $6.53 billion, a PE ratio of -31.76 and a beta of 0.41.
CG Oncology (NASDAQ:CGON – Get Free Report) last posted its earnings results on Friday, May 8th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.13). The company had revenue of $1.08 million for the quarter, compared to analysts’ expectations of $0.45 million. Sell-side analysts expect that CG Oncology, Inc. will post -2.66 EPS for the current fiscal year.
Insider Buying and Selling at CG Oncology
In related news, Director James Mulay sold 15,600 shares of the firm’s stock in a transaction on Friday, April 17th. The shares were sold at an average price of $73.01, for a total value of $1,138,956.00. Following the completion of the transaction, the director directly owned 15,600 shares of the company’s stock, valued at approximately $1,138,956. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 4.80% of the company’s stock.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. grew its holdings in shares of CG Oncology by 11.4% in the third quarter. Vanguard Group Inc. now owns 6,577,281 shares of the company’s stock valued at $264,933,000 after purchasing an additional 670,770 shares in the last quarter. Wellington Management Group LLP boosted its stake in CG Oncology by 8.8% during the fourth quarter. Wellington Management Group LLP now owns 5,999,790 shares of the company’s stock worth $249,111,000 after buying an additional 487,011 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in CG Oncology by 116.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,443,144 shares of the company’s stock worth $142,961,000 after buying an additional 1,854,386 shares during the period. State Street Corp boosted its stake in CG Oncology by 46.4% during the fourth quarter. State Street Corp now owns 2,996,695 shares of the company’s stock worth $124,423,000 after buying an additional 950,028 shares during the period. Finally, Alliancebernstein L.P. boosted its stake in CG Oncology by 15.0% during the second quarter. Alliancebernstein L.P. now owns 2,164,214 shares of the company’s stock worth $56,270,000 after buying an additional 281,637 shares during the period. 26.56% of the stock is owned by hedge funds and other institutional investors.
About CG Oncology
CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.
Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.
Read More
- Five stocks we like better than CG Oncology
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
- Plug Power Flips The Switch On Profitability
Receive News & Ratings for CG Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CG Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
